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Abstract
Stuttering is a speech disorder with disruption of verbal fluency which is occasionally present in patients with
Parkinson’s disease (PD). Long-term medical management of PD is frequently complicated by fluctuating motor
functions and dyskinesias. High-frequency deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an
effective treatment of motor fluctuations and is the most common surgical procedure in PD. Here we report the
re-occurrence and aggravation of stuttering following STN-DBS in two male patients treated for advanced PD. In
both patients the speech fluency improved considerably when the neurostimulator was turned off, indicating that
stuttering aggravation was related to neurostimulation of the STN itself, its afferent or efferent projections and/or
to structures localized in the immediate proximity. This report supports previous studies demonstrating that lesions
of the basal ganglia-thalamocortical motor circuit, including the STN, is involved in the development of stuttering.
In advanced PD STN-DBS is generally an effective and safe treatment. However, patients with PD and stuttering
should be informed about the risk of aggravated symptoms following surgical therapy.
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Background
Stuttering is a speech disorder with disruption of verbal
fluency characterized by involuntary repetitions or pro-
longations of sounds or syllables. The pathogenesis of
stuttering is not well understood. The most common
form of stuttering is developmental stuttering, which
evolves in childhood. Neurogenic or acquired stuttering
occurs after a definable brain damage, e.g. stroke, intra-
cerebral hemorrhage, or head trauma [1]. Acquired stut-
tering has been observed after lesions in a variety of
brain areas, including lesions in the striatum or thala-
mus. The occurrence of basal ganglia disorders, such as
Parkinson’s disease (PD), occasionally leads to a re-
emergence of recovered developmental stuttering [2].
PD is a movement disorder defined by the presence of
the cardinal motor features bradykinesia, rigidity and
tremor. Long-term medical management of PD is fre-
quently complicated by treatment-associated motor
complications in the form of fluctuating motor function
and dyskinesias. High-frequency deep brain stimulation
(DBS) of the subthalamic nucleus (STN) is an effective
treatment in advanced PD, improving all cardinal motor
symptoms and treatment-related motor complications
[3].
DBS of different parts of the basal ganglia and thala-
mus have become widely applied surgical procedures.
Observations on surgical and target related side effects
have provided novel insights into the function of these
parts of the brain. STN-DBS is currently the most com-
mon surgical procedure for patients with PD suffering
from intolerable motor complications despite optimal
medical treatment. Here we report the re-occurrence
and aggravation of stuttering following STN-DBS in two
male patients treated for advanced PD. This supports
previous studies indicating a role for the STN in the
development of stuttering.
Case presentations
Patient 1
This 65-year-old right-handed man was diagnosed with
PD at the age of 40 years. The disease had initially started
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with resting tremor on the right side, with subsequent
development of rigidity and bradykinesia. In parallel with
the parkinsonian symptoms he had developed stuttering.
He had no history of developmental stuttering. However,
he reported a history of an abnormally rapid speech since
his childhood. After more than 20 years of excellent
response to dopaminergic treatments he developed more
marked motor fluctuations, with tremor and freezing of
gait in periods of the day with poor effect of medication
(off-periods), and troublesome dyskinesias during periods
with good medication effect (on-periods). When preo-
perative evaluation for DBS was performed he was taking
2 mg of cabergoline and a total of 450 mg levodopa
in combination with 1400 mg of entacapone. After an
overnight withdrawal of dopaminergic treatment he had
a Unified Parkinson’s Disease Rating Scale (UPDRS)
motor score of 33 in the off-medication state. In the on-
medication state this score was 12. At the age of 63 years
surgery was performed using our standard procedure
with bilateral implantation of STN electrodes targeted in
accordance with preoperative MRI and intraoperative
microrecordings typical for the STN region.
After surgery the patient had marked improvement of
all parkinsonian cardinal features. Freezing of gait and
dyskinesias disappeared and there was a clear reduction
in motor fluctuations. However, the patient recognized a
marked worsening of speech fluency under effective
neurostimulation. One month after surgery the UPDRS
motor score in the on-stimulation off-medication state
was 12. The medication was reduced to 200 mg of levo-
dopa in combination with 800 mg entacapone. Stimula-
tion parameters were monopolar stimulation with
contacts 1 and 5 as cathodes with bilateral amplitudes
of 3.0 V, 60 μs pulse width and a frequency of 130 Hz.
With these settings he had severe stuttering. The main
problem consisted in difficulties initiating speech. Sing-
ing clearly reduced the stuttering. He had no hypopho-
nia or other speech abnormalities. No other side effects
occurred. The influence of stimulation settings on stut-
tering was assessed both during spontaneous speech and
during reading, and the examination was videotaped
with the patient and one of the authors (ED) blinded to
the stimulation parameters. After switching the neuro-
stimulator off, stuttering severity decreased quickly over
seconds. Programming sessions were undertaken in
order to optimize the stimulation parameters, but aggra-
vation of stuttering was clearly related to stimulation-
induced motor improvements.
At the last examination two years after the procedure
the speech dysfluency has showed some improvement.
Nevertheless, the patient occasionally switches the
device off during some activities as phone calls and pub-
lic talks. Stimulation parameters remained unchanged
with amplitudes of 3.0 V, 60 μs pulse width and a
frequency of 130 Hz. The medication was 300 mg of
levodopa in combination with 800 mg entacapone.
Patient 2
A 60-year-old right-handed man was diagnosed with PD
at the age of 38 years. Six years after receiving the diag-
noses he was treated with unilateral thalamotomy in the
left brain hemisphere. The disease gradually progressed
and he eventually developed marked rigidity, moderate
bradykinesia, but the tremor remained mild. He was eval-
uated for DBS because of marked motor fluctuations
with troublesome dyskinesias. He was then taking a total
of 1.08 mg pramipexol, 900 mg of levodopa and 900 mg
of entacapone daily. UPDRS motor scores were 35 in the
off-medication state and 8 in the on-medication state. At
the age of 53 years DBS electrodes were implanted in the
STN bilaterally.
Subthalamic stimulation had marked effects on all car-
dinal symptoms, and in the first months after surgery
the patient experienced no motor fluctuations or dyski-
nesias. The UPDRS motor score in the on-stimulation
off-medication state one month after surgery was 14. He
had stopped taking pramipexol and entacapone, but the
daily levodopa intake had remained at 900 mg per day.
The patient complained about marked increase in stut-
tering, a symptom which he had experienced in his
childhood and that re-emerged after he developed PD.
In addition, the patient also experienced dysarthria and
hypophonia, although these symptoms did not worsen
after the implantation. The relationship between stutter-
ing and neurostimulation was examined with the rater
blinded to stimulation parameters. Stuttering was clearly
related to neurostimulation and improvement of parkin-
sonian symptoms. The best motor improvements were
achieved with monopolar stimulation with contacts 2
and 6 as cathodes, bilateral amplitudes of 2.6 V, pulse
width 60 μs, and a frequency of 130 Hz. The patient
received intensive speech therapy and stuttering gradu-
ally improved over the first two years after surgery. At
the latest examination seven years after implantation the
UPDRS motor scores were 21 in the on-stimulation off-
medication and 11 in the on-stimulation on-medication
states. He was then taking a total of 1250 mg of levo-
dopa daily.
Conclusions
We describe two cases of aggravated stuttering after
STN-DBS in our series of 144 PD patients operated
between January 2001 and December 2007. One of the
patients had a history of developmental stuttering,
whereas the other patient first developed stuttering
years after receiving a diagnosis of PD. The main pro-
blem for both patients was difficulty in speech initiation,
with blocks and repetitions at word onset. Stuttering
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improved somewhat in the first postoperative months,
but remained a problem in daily life for patient 1. The
effect of neurostimulation on stuttering was clearly asso-
ciated with its effects on motor functions in these two
patients, and both patients had marked improvements
of motor fluctuations and dyskinesias. In addition, in
both patients the speech fluency improved considerably
when the neurostimulator was turned off. This indicates
that the electrodes were correctly placed, and that stut-
tering aggravation was related to neurostimulation of
the STN itself, its afferent or efferent projections, and/or
to structures localized in the immediate proximity.
Stuttering is a speech dysfluency. Verbal fluency tests
are often used to assess executive cognitive function,
and a decline in verbal fluency is consistently reported
following DBS for PD. Virtually all surveys assessing
phonological and/or semantic controlled word associa-
tion tasks after STN-DBS report a significant and long-
standing worsening of performance with respect to the
pre-operative level [4]. Similar findings have also been
obtained after pallidal and thalamic surgery [5].
Impaired verbal fluency after DBS has been interpreted
as impairment executive functioning [6]. However, the
identified aggravation of stuttering indicates that the
decline in verbal fluency measured after subthalamic sti-
mulation is, at least partly, not related to executive dys-
function, but a motor dysfunction of speech.
The STN is one of the main regulators of motor func-
tion related to the basal ganglia, through its fundamental
role within the basal ganglia-thalamocortical motor circuit
[7]. This motor circuit is postulated to play a key role in
the etiology of stuttering. The main dysfunction is thought
to be impairment in the ability of the basal ganglia to
produce timing cues for the initiation of the next motor
segment of speech [8]. The aggravated stuttering in the
two presented patients support that alterations of the
mentioned circuit at the level of the STN can influence
stuttering, and indicates that the basal ganglia play a cen-
tral role in speech production. The striking finding that
STN-stimulation is able to modulate stuttering severity
reversibly underlines the importance of the STN and the
basal ganglia network in general for motor activity regula-
tion during normal and abnormal speech.
Our findings are supported by two previous reports of
worsening of developmental and acquired stuttering fol-
lowing bilateral STN-DBS. Moretti et al reported speech
initiation problems in a PD patient without speech pro-
blems prior to DBS surgery [9]. In a report by Burghaus
and colleagues a marked worsening of stuttering was
found after STN-DBS [10]. In their patient developmen-
tal stuttering had re-occurred after the development of
PD. As in our patients, the stimulation-induced speech
dysfluency slowly improved in the first months after sur-
gery. Notably, unilateral stimulation of the STN in the
language-dominant hemisphere has been reported to
improve acquired stuttering [11]. It is unknown whether
this discrepancy could be explained by different place-
ments of the electrodes in the subthalamic region, dif-
ferences between unilateral and bilateral stimulation, or
different causes of stuttering in the reported patients.
The result of unilateral stimulation was unfortunately
not tested in our patients. Interestingly, it has recently
been reported that DBS of another part of the basal
ganglia, the internal globus pallidus, in two patients
treated for dystonia also induced stuttering [12]. The
sensorimotor GPi is connected to the same parts of the
motor circuit as the STN, and in patients with PD sti-
mulation of the GPi has similar effects on motor com-
plications as stimulation in the STN [13]. Thus,
alterations of the same network on different places may
induce or worsen stuttering.
It seems clear that lesions of the basal ganglia-
thalamocortical motor circuit are a frequent cause of
neurogenic stuttering [8]. Verbal fluency improves
following the administration of haloperidol and other
dopamine antagonists, a neurotransmitter in the
motor circuit [14]. Dopamine antagonists generally
markedly increase bradykinesia and rigidity of the
limbs in parkinsonian patients. This indicates that
speech and body motor systems might be neuroana-
tomically distinct. The findings in our two patients
support the hypothesis of a STN contribution to
speech processes both in developmental and neuro-
genic stuttering. Interestingly, a striking area of over-
activity was recently seen in the midbrain in people
with developmental stuttering relative to controls
[15].
STN-DBS is generally an effective and safe treatment [3].
However, prior to performing STN-DBS, patients with PD
and stuttering should be informed about the risk of aggra-
vated symptoms. Although stimulation-induced worsening
of stuttering seemed to improve over time, it could still be
a significant problem for the individual patient.
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